We are live on ! Find out more
IFRX icon

InflaRx

34 hedge funds and large institutions have $19.6M invested in InflaRx in 2025 Q4 according to their latest regulatory filings, with 13 funds opening new positions, 11 increasing their positions, 5 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

643% more call options, than puts

Call options by funds: $312K | Put options by funds: $42K

120% more repeat investments, than reductions

Existing positions increased: 11 | Existing positions reduced: 5

117% more first-time investments, than exits

New positions opened: 13 | Existing positions closed: 6

26% more funds holding

Funds holding: 2734 (+7)

1.21% more ownership

Funds ownership: 27.65%28.86% (+1.2%)

21% less capital invested

Capital invested by funds: $24.9M → $19.6M (-$5.3M)

Holders
34
Holders Change
+7
Holders Change %
+25.93%
% of All Funds
0.41%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
13
Increased
11
Reduced
5
Closed
6
Calls
$312K
Puts
$42K
Net Calls
+$270K
Net Calls Change
+$51K

IFRX Hedge Fund Activity: Q4 2025 in Review

34 of the 8,223 institutional investors tracked by Wall St. Rank reported a position in InflaRx (IFRX) for Q4 2025, worth a combined $19.6M — down 21% from $24.9M a quarter earlier.

Buyers outnumbered sellers: 13 funds opened new IFRX positions and 6 closed out — a net gain of 7 holders — while 11 added to existing stakes and 5 trimmed.

The largest buyer was Suvretta Capital Management, adding an estimated $1.8M. The largest seller was RA Capital Management, exiting entirely with an estimated $2.64M sold.

  • 34 institutional investors held InflaRx (IFRX) as of Q4 2025, up from 27 in Q3 2025.
  • Funds reported $19.6M of InflaRx stock for Q4 2025, down 21% quarter-over-quarter.
  • 13 funds opened new InflaRx positions in Q4 2025 and 6 closed out, a net change of +7 holders.
  • The largest InflaRx buyer in Q4 2025 was Suvretta Capital Management, an estimated $1.8M added.
  • The largest InflaRx seller in Q4 2025 was RA Capital Management, an estimated $2.64M sold.

Based on aggregated 13F filings for Q4 2025.